American Journal of Clinical Dermatology

, Volume 7, Issue 1, pp 7–12

Topical Macrolide Immunomodulators

A Role in the Treatment of Vitiligo?

Authors

    • Department of DermatologyRadboud University Nijmegen Medical Centre
  • Wynand H.P.M. Vissers
    • Department of DermatologyRadboud University Nijmegen Medical Centre
  • Marie-Jeanne P. Gerritsen
Current Opinion

DOI: 10.2165/00128071-200607010-00002

Cite this article as:
Tjioe, M., Vissers, W.H. & Gerritsen, M.P. Am J Clin Dermatol (2006) 7: 7. doi:10.2165/00128071-200607010-00002

Abstract

Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases, such as psoriasis, lichen planus, and even vitiligo, is expanding rapidly. It is generally accepted that autoimmune factors play an important role in vitiligo. In this article, the possible use and mechanism of topical macrolide immunomodulators in the treatment of vitiligo are discussed, together with the current state of clinical studies and case reports. These limited reports indicate that topical macrolide immunomodulators may play a role in the treatment of vitiligo, particularly in areas where use of potent corticosteroids is contraindicated.

Copyright information

© Adis Data Information BV 2006